SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.